Charakterizace p53 abnormalit u B-CLL pacientů ve vztahu k mutačnímu statusu IgVH a předchozí léčbě

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F05%3A00019164" target="_blank" >RIV/00216224:14110/05:00019164 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT

Popis výsledku v původním jazyce

Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVHsubtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the studywere to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). We used PCR and direct sequencing to

Název v anglickém jazyce

CHARACTERIZATION OF P53 ABNORMALITIES IN B-CLL PATIENTS IN RELATION TO IGVH MUTATION STATUS AND PREVIOUS TREATMENT

Popis výsledku anglicky

Background: Although the defects in the p53 gene predispose B CLL patients for inferior outcome, little is known about the reasons leading to inactivation of this tumor-suppressor. The p53 abnormalities were reported to be associated with unmutated IgVHsubtype and may thus arise as a consequence of its more aggressive behaviour, but some reports point also to potentially damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003; 10: 477 to 484). Aims: The aims of the studywere to determine the spectrum of p53 mutations in B CLL patients treated or monitored at our center and to correlate the data to mutation status of IgVH and to the previous treatment. Methods: We analyzed the status of the p53 gene in 144 patients diagnosed with B CLL of all stages using functional analysis in yeasts (FASAY) supplemented by Western blotting detection of p53 protein expression and I FISH detection of p53 deletions (LSI p53 17p13.1). We used PCR and direct sequencing to

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8445" target="_blank" >NR8445: In vitro sensitivita/resistence CLL buněk s inaktivovaným p53 na moderní léčbu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2005

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood

ISSN

0006-4971

e-ISSN

—

Svazek periodika

2005

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

1

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—